

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Gaush Meditech Ltd

高視医疗科技有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 2407)

VOLUNTARY ANNOUNCEMENT

GAUSH NEOTECH OBTAINED THE CE REGISTRATION CERTIFICATE FOR CORNEAL CONFOCAL MICROSCOPE

This announcement is made by Gaush Meditech Ltd (the “**Company**”, together with its subsidiaries, the “**Group**”) on a voluntary basis, to inform the shareholders and potential investors of the Company regarding the latest business development of the Group.

The board (the “**Board**”) of directors (the “**Director(s)**”) of the Company is pleased to announce that Gaush Neotech Ltd* (高視創新科技有限公司) (“**Gaush Neotech**”), a subsidiary of the Company, has recently been officially awarded the CE registration certificate for corneal confocal microscope (Certificate No.: 6208923CE01) by DEKRA. The attainment of this prestigious certification marks that the corneal confocal microscope of the Company fully complies with the stringent standards of the EU MDR and has received international authoritative recognition for its technical strength. This not only lays a solid foundation for the global market expansion and international development of the Company, but also establishes its strategic position to compete in the international high-end ophthalmic medical market by leveraging high-quality products and cutting-edge technological capabilities.

DEKRA, founded in 1925, is the world’s leading independent, non-listed expert organization in the field of testing, inspection and certification, serving a wide range of industries.

EU CE mark is a mandatory qualification certificate for medical devices entering the European market, demonstrating that the product complies with the EU MDR. It not only focuses on product safety and performance, but also emphasizes the risk management and clinical evaluation throughout the product’s entire lifecycle. The attainment of CE mark means that the corporate products meet the unified standards of the European Union in design, development, manufacturing, clinical validation and post-market supervision. It is one of the most recognized entry requirements in the global medical device market.

Shareholders and potential investors of the Company are advised to exercise caution when dealing in the shares of the Company.

By order of the Board
Gaush Meditech Ltd
Mr. Gao Tieta
Chairman and Executive Director

Hong Kong, April 10, 2026

As of the date of this announcement, the Board comprises Mr. Gao Tieta as Chairman and executive Director, Mr. Liu Xinwei, Mr. Zhao Xinli, Mr. Zhang Jianjun and Ms. Li Wenqi as executive Directors, Dr. David Guowei Wang as non-executive Director, and Mr. Feng Xin, Mr. Wang Li-Shin and Mr. Chan Fan Shing as independent non-executive Directors.